Your AI-Trained Oncology Knowledge Connection!
An expert discusses how the IMpower133 trial established atezolizumab plus chemotherapy as standard care for extensive-stage small cell lung cancer (ES-SCLC), improving overall survival from 10.3 to 12.3 months, though most patients still don't achieve long-term survival.
An expert discusses how the IMforte trial demonstrated that adding lurbinectedin to maintenance atezolizumab significantly improved progression-free survival (2.1 to 5.4 months) and overall survival (10.6 to 13.2 months) with an HR of 0.73.
An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.
An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.
An expert discusses how maintenance lurbinectedin plus atezolizumab should be followed by standard second-line tarlatamab therapy at progression, as the maintenance approach doesn't change subsequent treatment sequencing.
An expert discusses how maintenance lurbinectedin benefits patients across subgroups, including those with liver metastases, and may be considered for patients with brain metastases after radiation therapy, while emphasizing the importance of patient counseling about continued chemotherapy expectations.
